Browse Tag

ROche

Roche ranked the most sustainable healthcare company in the DJSI

1 min read

The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance. The DJSI family of indices serves as a benchmark for investors who integrate sustainability considerations into their portfolios. Roche has maintained its leadership through its sustainability strategy which is fully embedded in the company’s business and culture. “We are proud of being recognised once again for our sustainability efforts,” says Roche CEO Severin Schwan. “At Roche, we know that the…

Read More »

Roche ranked the most sustainable healthcare company in the DJSI

Published on
1 min read

The FINANCIAL — For the eleventh time, Roche has been recognised as the most sustainable company in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI). This is based on an in-depth analysis of economic, social and environmental performance. The DJSI family of indices serves as a benchmark for investors who integrate sustainability considerations…

You might be interested in

Roche to present new data across 16 blood disorders at the ASH 2020 Annual Meeting

Published on
3 mins read

The FINANCIAL — Roche  today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning…

You might be interested in

EU Commission approved Roche’s Tecentriq in combination with Avastin for the treatment of people with liver cancer

Published on
2 mins read

The FINANCIAL — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. “Tecentriq in combination with Avastin is the first treatment to be…

You might be interested in

Roche’s Tecentriq in combination with Avastin approved in China for people with liver cancer

Published on
3 mins read

The FINANCIAL — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. “Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma…

You might be interested in

Roche and Atea Pharmaceuticals partner to develop potential oral treatment for coronavirus patients

Published on
2 mins read

The FINANCIAL — Roche and Atea Pharmaceuticals, Inc. announced today that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute AT-527, Atea’s investigational oral direct-acting antiviral, to people around the globe. AT-527 acts by blocking the viral RNA polymerase enzyme needed for viral replication, and is currently being studied in…

You might be interested in

FDA fully approved Venclexta combinations for acute myeloid leukaemia

Published on
2 mins read

The FINANCIAL — Roche today announced that the US Food and Drug Administration (FDA) has granted full approval of Venclexta® (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly diagnosed acute myeloid leukaemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive…

You might be interested in

Roche reports first nine months of the year with 1% sales increase

Published on
4 mins read

The FINANCIAL — Commenting on the Group’s sales in the first nine months, Roche CEO Severin Schwan said: “Roche is at the forefront of the fight against COVID-19 with a growing portfolio of diagnostics solutions, the development of new medicines and a number of partnerships across the industry. With the recent launch of the rapid…

You might be interested in

Roche to launch high-volume coronavirus antigen test

Published on
2 mins read

THe FINANCIAL — Roche announced that it intends to launch a high-volume SARS-CoV-2 Antigen test as an aid in the diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. The test is planned to be made available at the end of 2020 for markets accepting the CE Mark. Roche also intends to file for…

You might be interested in